Catherine Frenette

机构：Gilead Sciences (United States) · ORCID：0000-0002-2245-8173

发表论文 148 篇 · 总被引 3768 次 · h-index 31

代表论文

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 437)
• ACG Clinical Guideline: Focal Liver Lesions (2024 · The American Journal of Gastroenterology · 被引 101)
• Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the “all-comers” protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium (2023 · American Journal of Transplantation · 被引 23)
• The impact of right atrial pressure on outcomes in patients undergoing TIPS, an ALTA group study (2023 · Hepatology · 被引 20)
• Predictors of long-term clinical outcomes after TIPS: An ALTA group study (2024 · Hepatology · 被引 13)
• Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase (2024 · Journal of Viral Hepatitis · 被引 11)